NasdaqCM - Nasdaq Real Time Price USD

Surrozen, Inc. (SRZN)

7.10

+0.25

+(3.65%)

At close: May 16 at 4:00:00 PM EDT

7.10

0.00

(0.00%)

After hours: May 16 at 4:05:11 PM EDT

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt

GlobeNewswire 2 days ago

SRZN
+3.65%

SRZNW
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging it

GlobeNewswire 7 days ago

SRZN
+3.65%

SRZNW
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential

GlobeNewswire last month

SRZN
+3.65%

SRZNW
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies Company discontinues clinical development of SZN-043 in severe alcohol associated hepatitis SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Surrozen, I

GlobeNewswire last month

SRZN
+3.65%

SRZNW
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

SRZN
+3.65%

SRZNW
Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at two upcoming healthcare investor conferences. Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024 Fireside Chat at 3:00 PM ET / 1

GlobeNewswire 6 months ago

SRZN
+3.65%

SRZNW
Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&D pipeline Received $10 million milestone payment from Boehringer Ingelheim strategic collaboration on SZN-413 in retinal vascular associated diseases SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “C

GlobeNewswire 6 months ago

SRZN
+3.65%

SRZNW
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary FibrosisSOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic research collaboration with privately-he

GlobeNewswire 6 months ago

SRZN
+3.65%

SRZNW
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/Integrated (Wnt) signaling, designed using Surrozen’s SWAP™ technology SZN-413 offers the possibility of restoring retinal function in patients living with retinal vascular diseases SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SR

GlobeNewswire 7 months ago

SRZN
+3.65%

SRZNW
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 8 months ago

SRZN
+3.65%

SRZNW
Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted Protein Degradation technologies resulting in robust Wnt signal activation in bispecific antibodies based on the Company's SWEETS technology platform SOUTH SAN FRANCISCO, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a comp

GlobeNewswire 8 months ago

SRZN
+3.65%

SRZNW
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific antibodies enhanced Wnt-signal activation through the unique TPD platform SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulat

GlobeNewswire 10 months ago

SRZN
+3.65%

SRZNW
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1a trial of SZN-043 demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis SOUTH SAN FRANCISC

GlobeNewswire 10 months ago

SRZN
+3.65%

SRZNW
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical

GlobeNewswire 11 months ago

SRZN
+3.65%

SRZNW

Performance Overview

Return	SRZN	S&P 500 (^GSPC)
YTD	-50.52%	+1.30%
1-Year	-30.05%	+12.48%
3-Year	-79.60%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Surrozen, Inc. (SRZN)

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Performance Overview